Cathelicidin Insufficiency in Patients with Fatal Leptospirosis.
Lindow. Janet C JC; Wunder. Elsio A EA; Popper. Stephen J SJ; Min. Jin-Na JN; Mannam. Praveen P; Srivastava. Anup A; Yao. Yi Y; Hacker. Kathryn P KP; Raddassi. Khadir K; Lee. Patty J PJ; Montgomery. Ruth R RR; Shaw. Albert C AC; Hagan. Jose E JE; Araújo. Guilherme C GC; Nery. Nivison N; Relman. David A DA; Kim. Charles C CC; Reis. Mitermayer G MG; Ko. Albert I AI
Key Findings
- Fatal leptospirosis patients showed reduced cathelicidin (LL‑37) expression in blood
- Low cathelicidin and RANTES levels were linked to higher bacterial loads and higher risk of death
- Administering LL‑37 to hamsters with lethal leptospirosis reduced bacterial counts and increased survival
Practical Outcomes
- For biohackers, this suggests that boosting cathelicidin (e.g., via vitamin D or other known inducers) might improve resistance to severe bacterial infections. However, direct LL‑37 supplementation is not yet a proven human therapy, so focus on supporting natural cathelicidin production and monitoring immune health.
Summary
People who die from severe leptospirosis have lower levels of the natural antibiotic peptide LL‑37 (cathelicidin) and higher bacterial loads, while survivors have stronger immune responses. Giving LL‑37 to infected hamsters lowered the bacteria and helped them survive, showing the peptide can be protective.
Abstract
Leptospirosis causes significant morbidity and mortality worldwide; however, the role of the host immune response in disease progression and high case fatality (>10-50%) is poorly understood. We conducted a multi-parameter investigation of patients with acute leptospirosis to identify mechanisms associated with case fatality. Whole blood transcriptional profiling of 16 hospitalized Brazilian patients with acute leptospirosis (13 survivors, 3 deceased) revealed fatal cases had lower expression of the antimicrobial peptide, cathelicidin, and chemokines, but more abundant pro-inflammatory cytokine receptors. In contrast, survivors generated strong adaptive immune signatures, including transcripts relevant to antigen presentation and immunoglobulin production. In an independent cohort (23 survivors, 22 deceased), fatal cases had higher bacterial loads (P = 0.0004) and lower anti-Leptospira antibody titers (P = 0.02) at the time of hospitalization, independent of the duration of illness. Low serum cathelicidin and RANTES levels during acute illness were independent risk factors for higher bacterial loads (P = 0.005) and death (P = 0.04), respectively. To investigate the mechanism of cathelicidin in patients surviving acute disease, we administered LL-37, the active peptide of cathelicidin, in a hamster model of lethal leptospirosis and found it significantly decreased bacterial loads and increased survival. Our findings indicate that the host immune response plays a central role in severe leptospirosis disease progression. While drawn from a limited study size, significant conclusions include that poor clinical outcomes are associated with high systemic bacterial loads, and a decreased antibody response. Furthermore, our data identified a key role for the antimicrobial peptide, cathelicidin, in mounting an effective bactericidal response against the pathogen, which represents a valuable new therapeutic approach for leptospirosis.
Study Information
pubmed
2016
2016-11-03T00:00:00.000Z
10.1371/journal.ppat.1005943
34
80